MeiraGTx Holdings plc Increase Decrease In Operating Lease Liability
MeiraGTx Holdings plc (MGTX) reported Increase Decrease In Operating Lease Liability of -$73.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2025-11-13
- MeiraGTx Holdings plc increase decrease in operating lease liability for the quarter ending 2025-09-30 was $65.00K.
- MeiraGTx Holdings plc increase decrease in operating lease liability for the quarter ending 2025-06-30 was -$209.00K.
- MeiraGTx Holdings plc increase decrease in operating lease liability for the quarter ending 2025-03-31 was $71.00K.
- MeiraGTx Holdings plc increase decrease in operating lease liability for the quarter ending 2024-12-31 was $174.00K.
- MeiraGTx Holdings plc increase decrease in operating lease liability for fiscal 2024 was $16.00K.
- MeiraGTx Holdings plc increase decrease in operating lease liability for fiscal 2023 was -$222.00K.
- MeiraGTx Holdings plc increase decrease in operating lease liability for fiscal 2022 was -$153.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-09-30 | $65.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$144.00K derived: sum of 2 quarters · filed 2025-11-13 | -$73.00K 10-Q · filed 2025-11-13 | $101.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | -$209.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$138.00K 10-Q · filed 2025-08-14 | $36.00K derived: sum of 3 quarters · filed 2025-08-14 | -$22.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-03-31 | $71.00K 10-Q · filed 2025-05-13 | $245.00K derived: sum of 2 quarters · filed 2025-05-13 | $187.00K derived: sum of 3 quarters · filed 2025-11-13 | $123.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-12-31 | $174.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $116.00K derived: sum of 2 quarters · filed 2025-11-13 | $52.00K derived: sum of 3 quarters · filed 2025-11-13 | $16.00K 10-K · filed 2025-03-13 |
| 2024-09-30 | -$58.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$122.00K derived: sum of 2 quarters · filed 2025-11-13 | -$158.00K 10-Q · filed 2025-11-13 | -$227.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$64.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$100.00K 10-Q · filed 2025-08-14 | -$169.00K derived: sum of 3 quarters · filed 2025-08-14 | -$218.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$36.00K 10-Q · filed 2025-05-13 | -$105.00K derived: sum of 2 quarters · filed 2025-05-13 | -$154.00K derived: sum of 3 quarters · filed 2025-05-13 | -$234.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$69.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$118.00K derived: sum of 2 quarters · filed 2025-03-13 | -$198.00K derived: sum of 3 quarters · filed 2025-03-13 | -$222.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | -$49.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$129.00K derived: sum of 2 quarters · filed 2024-11-13 | -$153.00K 10-Q · filed 2024-11-13 | -$221.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$80.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$104.00K 10-Q · filed 2024-08-12 | -$172.00K derived: sum of 3 quarters · filed 2024-08-12 | |
| 2023-03-31 | -$24.00K 10-Q · filed 2024-05-09 | -$92.00K derived: sum of 2 quarters · filed 2024-05-09 | ||
| 2022-12-31 | -$68.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -$153.00K 10-K · filed 2024-03-15 | ||
| 2022-09-30 | -$85.00K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |